Major Update: Remdesivir for Adults With COVID-19
A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points
Anjum S. Kaka, MD; Roderick MacDonald, MS; Nancy Greer, PhD; Kathryn Vela, MLIS; Wei Duan-Porter, MD, PhD; Adam Obley, MD; and Timothy J. Wilt, MD, MPH

Background: Remdesivir is being studied and used for treatment of coronavirus disease 2019 (COVID-19).

Purpose: To update a previous review of remdesivir for adults with COVID-19, including new meta-analyses of patients with COVID-19 of any severity compared with control.

Data Sources: Several sources from 1 January 2020 through 7 December 2020.

Study Selection: English-language, randomized controlled trials (RCTs) of remdesivir for COVID-19. New evidence is incorporated by using living review methods.

Data Extraction: 1 reviewer abstracted data; a second reviewer verified the data. The Cochrane Risk of Bias Tool and GRADE (Grading of Recommendations Assessment, Development and Evaluation) method were used.

Data Synthesis: The update includes 5 RCTs, incorporating data from a new large RCT and the final results of a previous RCT. Compared with control, a 10-day course of remdesivir probably results in little to no reduction in mortality (risk ratio [RR], 0.93 [95% CI, 0.82 to 1.06]; 4 RCTs) but may result in a small reduction in the proportion of patients receiving mechanical ventilation (RR, 0.71 [CI, 0.56 to 0.90]; 3 RCTs). Remdesivir probably results in a moderate increase in the percentage of patients who recovered and a moderate decrease in serious adverse events and may result in a large reduction in time to recovery. Effect on hospital length of stay or percentage remaining hospitalized is mixed. Compared with a 10-day course for those not requiring ventilation at baseline, a 5-day course may reduce mortality, the need for ventilation, and serious adverse events while increasing the percentage of patients who recovered or clinically improved.

Limitation: Summarizing findings was challenging because of varying disease severity definitions and outcomes.

Conclusion: In hospitalized adults with COVID-19, remdesivir probably results in little to no mortality difference but probably improves the percentage recovered and reduces serious harms and may result in a small reduction in the proportion receiving ventilation. For patients not receiving ventilation, a 5-day course may provide greater benefits and fewer harms with lower drug costs than a 10-day course.

Primary Funding Source: U.S. Department of Veterans Affairs.

Ann Intern Med. 2021;174:663-672. doi:10.7326/M20-8148 Annals.org
For author, article, and disclosure information, see end of text.
This article was published at Annals.org on 9 February 2021.

See also:
Related article ................................. 673
Web-Only
Supplement
Our original review mainly compared the effectiveness of remdesivir versus placebo. However, our new primary analyses, developed in consultation with the American College of Physicians Scientific Medical Policy Committee, focused on comparing a 10-day course of remdesivir with a combined control of placebo and standard care for all outcomes in patients with COVID-19 of any severity. We also provide results for the different controls (placebo and standard care) separately and the COE for outcomes we could not pool. We conducted sensitivity analyses by baseline COVID-19 severity and by combining remdesivir 5- and 10-day courses.

We include new analyses and data on all-cause mortality, recovery or improvement, need for ventilation, hospital length of stay, and percentage of patients hospitalized between days 7 and 14. We also provide new mortality analyses by subgroups defined by baseline respiratory support requirements: no oxygen, supplemental oxygen but not ventilation, and ventilation. These categories approximate National Institutes of Health and World Health Organization (WHO) definitions of moderate, severe, and critical COVID-19, respectively (Supplement Table 10, available at Annals.org).

We reanalyzed aggregate COE on the effectiveness of a 5- versus 10-day course of remdesivir by combining RCTs that included patients with moderate and severe COVID-19 on the basis of previously published data. These reanalyses were done in consultation with the American College of Physicians because they were deemed clinically reasonable and useful.

Role of the Funding Source
This work is based on a living rapid review done for the U.S. Department of Veterans Affairs Evidence Synthesis Program (10). Funding for that review was provided by the Veterans Health Administration Office of Research and Development, Health Services Research and Development Service. The funding source assigned the topic but was not involved in data collection, analysis, manuscript preparation, or submission.

Results
The updated literature search identified 476 citations (Appendix Figure, available at Annals.org). We identified 2 new eligible publications: final results from previously published preliminary findings of a placebo-controlled RCT (ACTT-1 [Adaptive COVID-19 Treatment Trial]) (5) and interim published results of an open-label RCT of remdesivir versus standard care (Solidarity) (4). Therefore, a total of 5 RCTs were eligible for inclusion in this update (4, 5, 11-13).

Overview of All Randomized Trials (5 Trials)
All studies evaluated remdesivir administered intravenously, with 200 mg on day 1 and 100 mg on subsequent days. Studies excluded patients who were pregnant or had severe kidney or liver dysfunction. Four RCTs included patients with severe COVID-19 (4, 5, 11, 13); 1 included only patients with moderate COVID-19 (12). Four RCTs compared remdesivir with control (placebo or standard care) (4, 5, 12, 13), and 1 RCT compared a 5- versus a 10-day remdesivir course (11). The primary outcome in 4 RCTs was time to clinical improvement or symptom recovery; in 1 RCT (Solidarity) (4), it was in-hospital all-cause mortality through 28 days. Details about study characteristics, outcomes, and harms are reported in Supplement Tables 3 to 8, and information on risk of bias is presented in Supplement Table 9.

New Findings From ACTT-1 and Solidarity
ACTT-1 (Final Report)
Final results from ACTT-1 (n = 1062), a double-blind, placebo-controlled study (5), were generally similar to those of the preliminary report and provide additional mortality information through 29 days. Review of interim results had prompted trial investigators to end the placebo group early. Compared with the placebo group, patients who were randomly assigned to receive up to a 10-day course of remdesivir had a shorter time to recovery. Remdesivir increased the percentage of patients who recovered and resulted in a numerically lower mortality rate at 29 days. It reduced the percentage of patients receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) on day 15. Remdesivir reduced serious adverse events and resulted in a moderate, nonsignificant reduction in any adverse event compared with placebo. The effectiveness of remdesivir in shortening time to recovery did not vary by prespecified subgroups of age (categories), sex, symptom duration (<10 vs. >10 days), disease severity (mild or moderate vs. severe), or concomitant corticosteroid use (23% of all participants). However, in the subset of patients with severe disease who were receiving invasive mechanical ventilation or ECMO (critical COVID-19, n = 285 [27% of enrollees]), time to recovery was not improved with remdesivir.

Solidarity
The WHO’s Solidarity trial, the largest published RCT of remdesivir (n = 5472), was a simple, open-label, adaptive study comparing a 10-day course of remdesivir with a “standard-of-care” control in adults hospitalized with COVID-19 (4). The primary outcome was in-hospital mortality through 28 days. Among all participants, 65% were older than 50 years and 63% were men; 24% of participants were receiving no oxygen, 67% were receiving supplemental oxygen, and 9% were receiving ventilation (invasive or noninvasive mechanical ventilation or ECMO) at baseline. Compared with standard care, remdesivir did not reduce in-hospital 28-day mortality, either overall or in any subgroup. The effects of remdesivir on mortality did not vary by age, sex, comorbid conditions, current smoking status, geographic location, presence of bilateral pulmonary infiltrates, concomitant corticosteroid use (48% of participants), duration of hospitalization before randomization (0, 1, or ≥2 days), or respiratory support at baseline, although there was a suggestion of increased mortality with remdesivir in patients receiving ventilation at baseline. Among participants not receiving ventilation at baseline, remdesivir did not reduce the subsequent need for ventilation. Remdesivir did not decrease the percentage of persons hospitalized at day 7 or 14.

Summary Findings
See Figures 1 and 2; the Table; and the Appendix Table, available at Annals.org.
Remdesivir 10-Day Course Compared With Control (Placebo or Standard Care [4 Trials])

Of the 4 RCTs comparing remdesivir with control (placebo or standard care), 2 used a placebo (5, 13) and 2 used standard care as the control (4, 12) (Table and Appendix Table). One RCT included only patients with moderate disease (12), but the other 3 RCTs included patients with more severe COVID-19, including critical disease (4, 5, 13). We used 28-day (instead of 11-day) data from SIMPLE-2 (Study to Evaluate the Safety and Antiviral Activity of Remdesivir [GS-5734] in Participants With Moderate Coronavirus Disease [COVID-19] Compared to Standard of Care Treatment) (12) to allow pooling with studies that had longer follow-up.

All-Cause Mortality

Our updated analyses, including new results from Solidarity, show that remdesivir, compared with control, probably results in little to no difference in mortality (risk ratio [RR], 0.93 [95% CI, 0.82 to 1.06]; absolute risk difference [ARD], −0.8% [CI, −2.2% to 0.7%]; 4 RCTs) (moderate COE) (Figure 1, top). Mortality results varied little when we did sensitivity analyses that included results of a 5-day course of remdesivir.

Figure 1. Mortality for remdesivir 10-d course vs. control (placebo or standard care).

| Study, Year (Reference) | Control | Remdesivir | Control | RR | RR (95% CI) |
|-------------------------|---------|------------|---------|----|-------------|
| Beigel et al [ACTT-1], 2020 (5) | Placebo | 59 | 541 | 77 | 521 | 0.74 (0.54–1.01) |
| Wang et al, 2020 (13) | Placebo | 22 | 158 | 10 | 78 | 1.09 (0.54–2.18) |
| Spinner et al [SIMPLE-2], 2020 (12) | Usual care | 2 | 193 | 4 | 200 | 0.52 (0.10–2.80) |
| Pan et al [Solidarity], 2020 (4) | Usual care | 301 | 2743 | 304 | 2708 | 0.98 (0.84–1.14) |
| **Fixed-effects model** | | 384 | 3635 | 394 | 3507 | 0.93 (0.82–1.06) |

**Heterogeneity: $I^2 = 6\%$**

| Study, Year (Reference) | Control | Remdesivir | Control | RR | RR (95% CI) |
|-------------------------|---------|------------|---------|----|-------------|
| Beigel et al [ACTT-1], 2020 (5) | Placebo | 3 | 75 | 3 | 63 | 0.84 (0.18–4.02) |
| Spinner et al [SIMPLE-2], 2020 (12) | Usual care | 2 | 193 | 4 | 200 | 0.52 (0.10–2.80) |
| Pan et al [Solidarity], 2020 (4) | Usual care | 11 | 661 | 13 | 664 | 0.85 (0.38–1.88) |
| **Fixed-effects model** | | 16 | 929 | 20 | 927 | 0.78 (0.41–1.50) |

**Heterogeneity: $I^2 = 0\%$**

| Study, Year (Reference) | Control | Remdesivir | Control | RR | RR (95% CI) |
|-------------------------|---------|------------|---------|----|-------------|
| Beigel et al [ACTT-1], 2020 (5) | Placebo | 9 | 232 | 25 | 203 | 0.32 (0.15–0.66) |
| Wang et al, 2020 (13) | Placebo | 11 | 129 | 7 | 68 | 0.83 (0.34–2.04) |
| Pan et al [Solidarity], 2020 (4) | Usual care | 192 | 1828 | 219 | 1811 | 0.87 (0.72–1.04) |
| **Fixed-effects model** | | 212 | 2189 | 251 | 2082 | 0.81 (0.68–0.96) |

**Ventilated or ECMO at baseline**

| Study, Year (Reference) | Control | Remdesivir | Control | RR | RR (95% CI) |
|-------------------------|---------|------------|---------|----|-------------|
| Beigel et al [ACTT-1], 2020 (5): high-flow oxygen or noninvasive ventilation | Placebo | 19 | 95 | 20 | 98 | 0.98 (0.56–1.72) |
| Beigel et al [ACTT-1], 2020 (5): ventilation | Placebo | 28 | 131 | 29 | 154 | 1.14 (0.71–1.81) |
| Wang et al, 2020 (13) | Placebo | 11 | 29 | 3 | 10 | 1.26 (0.44–3.63) |
| Pan et al [Solidarity], 2020 (4) | Usual care | 98 | 254 | 71 | 233 | 1.27 (0.99–1.62) |
| **Fixed-effects model** | | 156 | 509 | 123 | 495 | 1.19 (0.98–1.46) |

**Ventilated or ECMO at baseline**

The black diamonds reflect pooled results from randomized controlled trials (listed above) that enrolled patients in the corresponding respiratory support subgroups. ACTT-1 = Adaptive COVID-19 Treatment Trial; ECMO = extracorporeal membrane oxygenation; RR = risk ratio; SIMPLE-2 = Study to Evaluate the Safety and Antiviral Activity of Remdesivir [GS-5734] in Participants With Moderate Coronavirus Disease [COVID-19] Compared to Standard of Care Treatment. Top. Overall. Bottom. Results by initial respiratory status.
Based on pooled post hoc subgroup analyses, remdesivir’s effect on mortality may vary by baseline respiratory support requirements (Figure 1, bottom). Compared with control, remdesivir may result in little to no decrease in mortality in patients not requiring supplemental oxygen (RR, 0.78 [CI, 0.41 to 1.50]; ARD, −0.2% [CI, −0.8% to 0.4%]; 3 RCTs), a small decrease in patients receiving supplemental oxygen but not needing ventilation (RR, 0.81 [CI, 0.68 to 0.96]; ARD, −2.3% [CI, −4.2% to −0.4%]; 3 RCTs), and a moderate increase in patients receiving ventilation (RR, 1.19 [CI, 0.98 to 1.46]; ARD, 4.9% [CI, −0.6% to 10.3%]; 3 RCTs). Remdesivir’s effect on mortality may not vary by other patient, disease, or treatment factors, including age, sex, race/ethnicity, current smoking status, comorbid conditions, geographic location, presence of bilateral pulmonary

### Table: Pooled Analyses of Remdesivir's Effect on Mortality

| Study, Year (Reference) | Control | Remdesivir | Control |
|-------------------------|---------|------------|---------|
|                         | Events, n | Total, n | Events, n | Total, n | RR | RR (95% CI) |
| Beigel et al [ACTT-1], 2020 (5) | Placebo | 399 | 541 | 352 | 521 | 1.09 (1.01–1.18) |
| Wang et al, 2020 (13) | Placebo | 106 | 150 | 49 | 77 | 1.11 (0.91–1.35) |
| Spinner et al [SIMPLE-2], 2020 (12) | Usual care | 178 | 193 | 170 | 200 | 1.09 (1.01–1.17) |
| Fixed-effects model | 683 | 884 | 571 | 798 | 1.09 (1.03–1.15) |

### Figure 2: Nonmortality Outcomes for Remdesivir 10-d Course vs. Control (Placebo or Standard Care)

- **Top:** Proportion of patients recovered.
- **Middle:** Need for invasive ventilation/ECMO.
- **Bottom:** Patients with ≥1 serious adverse event.

* For the pooled trials, defined as proportion receiving invasive ventilation/ECMO (new vs. continued from baseline) at follow-up (ACTT-1 on day 15, Wang et al on day 14, and SIMPLE-2 on day 11).

† Unpooled Solidarity trial, defined as subsequent need for ventilation in those not receiving ventilation at baseline (through day 28).
### Table. Summary of Conclusions and Updated Findings for Randomized Trials of Remdesivir

| Outcome | Conclusions From Last Report Version | New Trial Results/Analyses | Updated Conclusions |
|---------|--------------------------------------|---------------------------|--------------------|
| **Remdesivir 10-d course vs. control (placebo or SC) for any severity of COVID-19; 4 trials (n = 7171) (4, 5, 12, 13)** | | | |
| Mortality | No pooled analysis | 1 new RCT vs. SC (4) and final results from 1 RCT (5) vs. placebo | Remdesivir 10-d course probably results in little to no difference vs. control (4, 5, 12, 13). Subgroup analyses (post hoc) based on initial respiratory support: Not requiring supplemental O₂ may result in little to no difference vs. control (4, 5, 12). Requiring supplemental O₂ but not mechanically ventilated: may result in a small reduction vs. control (4, 5, 13). Requiring mechanical ventilation/ECMO*: may result in a moderate increase vs. control (4, 5, 12). |
| Proportion recovered† | No pooled analysis | Final results from 1 RCT vs. placebo (5) and longer-term (28-d) results from 1 RCT vs. SC (12) | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. control (4, 5, 12, 13). |
| Proportion with clinical improvement‡ | No pooled analysis | Longer-term (28-d) results from 1 RCT vs. SC (12) | Remdesivir 10-d course may result in a moderate increase in percentage with clinical improvement vs. control (12, 13). |
| Hospital length of stay | No pooled analysis | – | – |
| Time to recovery/clinical improvement | No pooled analysis | Final results from 1 RCT vs. placebo (5) | Remdesivir 10-d course may result in up to a large reduction in median time to recovery or a moderate reduction in time to clinical improvement vs. control (5, 12, 13). Subgroup analyses (prespecified) (5): Time to recovery did not vary by age, sex, symptom duration (≤10 vs. >10 d), or disease severity (mild/moderate or severe): Remdesivir 10-d course may result in a moderate to large reduction vs. placebo (5, 13). |
| Proportion receiving invasive ventilation/ECMO at follow-up | No pooled analysis | Final results from 1 RCT vs. placebo (5) | Remdesivir 10-d course may result in a small reduction vs. placebo (5, 12, 13). |
| Proportion with new need for ventilation | NR | 1 new RCT vs. SC (4) | Remdesivir 10-d course probably results in little to no difference vs. control (4). |
| Serious adverse events | No pooled analysis | Final results from 1 RCT (5) | Remdesivir 10-d course probably results in a moderate reduction vs. control (5, 12, 13). |
| **Remdesivir 10-d course vs. placebo for any severity of COVID-19; 2 trials (n = 1299) (5, 13)** | | | |
| Mortality | Remdesivir 10-d course may result in a small reduction vs. placebo (5, 13) | Final results from 1 RCT (5) | No change in conclusions |
| Proportion recovered† | Remdesivir 10-d course probably results in a moderate increase vs. placebo (5, 13) | Final results from 1 RCT (5) | No change in conclusions |
| Proportion with clinical improvement‡ | Remdesivir 10-d course may result in a moderate increase vs. placebo (13) | No new evidence | No change in conclusions |
| Hospital length of stay | Remdesivir 10-d course may result in little to no difference vs. placebo (13) | Final results from 1 RCT (5) | Remdesivir 10-d course may result in a moderate reduction vs. placebo (5, 13). |
| Time to recovery or clinical improvement | Remdesivir 10-d course may result in a small reduction vs. placebo (5, 13) Subgroup analyses (prespecified) (5): Time to recovery did not vary by age, sex, symptom duration (≤10 vs. >10 d), or disease severity (mild/moderate or severe): Remdesivir 10-d course may result in a moderate to large reduction vs. placebo (5, 13). | Final results from 1 RCT (5) | Remdesivir 10-d course may result in a moderate to large reduction vs. placebo (5, 13). |
| Proportion receiving mechanical ventilation/ECMO at follow-up | Remdesivir 10-d course may result in a small reduction vs. placebo (5, 13) | Final results from 1 RCT (5) | Remdesivir 10-d course may result in a moderate reduction vs. placebo (5, 13). |

Continued on following page
### Table—Continued

| Outcome                                      | Conclusions From Last Report Version                                      | New Trial Results/Analyses                                      | Updated Conclusions |
|----------------------------------------------|--------------------------------------------------------------------------|----------------------------------------------------------------|--------------------|
| Serious adverse events                       | Remdesivir 10-d course probably results in a moderate reduction vs. placebo (5, 13) | Final results from 1 RCT (5)                                    | No change in conclusions |
| **Remdesivir 10-d course vs. SC for any severity of COVID-19; 2 trials (n = 5872) (4, 12)** | | | |
| Mortality                                    | Remdesivir 10-d course may result in a small reduction vs. SC (12)         | 1 new RCT (4)                                                    | Remdesivir 10-d course probably results in little to no difference vs. SC (4, 12) |
| Proportion recovered†                        | Remdesivir 10-d course may result in a small increase in percentage recovered vs. SC (12) | Longer-term (28-d) results from 1 RCT vs. SC (12)               | Remdesivir 10-d course may result in a moderate increase in percentage recovered vs. SC (12) |
| Proportion with clinical improvement‡       | Remdesivir 10-d course may result in a small increase vs. SC (12)         | Longer-term (28-d) results from 1 RCT (12)                      | Remdesivir 10-d course may result in a moderate increase in percentage recovered vs. SC (12) |
| Hospital length of stay                      | NR                                                                       | Reanalysis of previously published data (COE not assessed) (4, 12) | The percentage of patients hospitalized on days 7-14 did not differ between the remdesivir 10-d course and SC groups (4, 12) |
| Time to recovery or clinical improvement     | Insufficient COE (12)                                                     | –                                                              | – |
| Proportion receiving mechanical ventilation/ECMO at follow-up | Remdesivir 10-d course may result in a small reduction vs. SC (12)         | No new evidence                                                  | No change in conclusions |
| Proportion with new need for ventilation     | NR                                                                       | 1 new RCT (4)                                                    | Remdesivir 10-d course probably results in little to no difference vs. SC (4) |
| Serious adverse events                       | Remdesivir 10-d course may result in a small reduction vs. SC (12)         | No new evidence                                                  | No change in conclusions |
| **Remdesivir 5-d course vs. SC for moderate COVID-19; 1 trial (n = 399) (12)** | | | |
| Mortality                                    | Remdesivir 5-d course may result in a small reduction vs. SC               | No new evidence                                                  | No change in conclusions |
| Proportion recovered†                        | Remdesivir 5-d course may result in a moderate increase vs. SC             | Longer-term (28-d) results                                      | No change in conclusions |
| Proportion with clinical improvement‡       | Remdesivir 5-d course may result in a moderate increase vs. SC             | Longer-term (28-d) results                                      | No change in conclusions |
| Hospital length of stay                      | NR                                                                       | Reanalysis of previously published data (COE not assessed)       | The percentage of persons hospitalized at days 11 and 14 did not differ between the remdesivir 5-d and SC groups |
| Time to recovery or clinical improvement     | Remdesivir 5-d course may result in a small reduction vs. SC               | No new evidence                                                  | No change in conclusions |
| Proportion receiving mechanical ventilation/ECMO at follow-up | Remdesivir 5-d course may result in a small reduction vs. SC               | No new evidence                                                  | No change in conclusions |
| Serious adverse events                       | Remdesivir 5-d course may result in a small reduction vs. SC               | No new evidence                                                  | No change in conclusions |
| **Remdesivir 5-d course vs. 10-d course for moderate and severe COVID-19 (excludes critical COVID-19); 2 trials (n = 798) (11, 12)** | | | |
| Mortality                                    | Remdesivir 5-d course may result in a small reduction vs. 10-d course (11, 12) | COE reanalysis of previously published data                      | No change in conclusions |
| Proportion recovered†                        | Remdesivir 5-d course may result in a moderate increase vs. 10-d course (11, 12) | COE reanalysis of previously published data                      | No change in conclusions |
| Proportion with clinical improvement‡       | Remdesivir 5-d course may result in a small (12) to moderate increase (11) vs. 10-d course | COE reanalysis of previously published data                      | Remdesivir 5-d course may result in a moderate increase vs. 10-d course (11, 12) |
| Hospital length of stay                      | NR                                                                       | Reanalysis of previously published data (COE not assessed)       | The percentage of persons hospitalized at days 11 and 14 did not differ between the remdesivir 5-d and 10-d course groups (12) |

*Continued on following page*
infiltrates, concomitant corticosteroid use, duration of hospitalization before randomization (0, 1, or ≥2 days) (4), or symptom duration (≤10 vs. >10 days) (13).

**Proportion Recovered**

New analyses show that remdesivir probably results in a moderate increase in the proportion of patients who recovered (ARD, 6.5% [CI, 2.4% to 10.7%]; 3 RCTs) (moderate COE) (Figure 2, top). Recovery was defined as discharge from the hospital or hospitalization for infection control purposes only (5), or discharge from the hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care (11-13).

**Proportion Clinically Improved**

New analyses show that remdesivir versus control may result in a moderate increase in the proportion clinically improved (range of ARDs, 7.2% to 7.5%; 2 RCTs) (low COE). Clinical improvement was defined as a 2-point reduction in patients’ admission status on a 6-point ordinal scale (1 = live discharge to 6 = death) or live discharge from the hospital, whichever came first (13), or as an improvement of at least 2 points from baseline on a 7-point ordinal scale (1 = death to 7 = hospital discharge) (11, 12).

**Hospital Length of Stay and Percentage Hospitalized**

New analyses show that remdesivir versus placebo may moderately reduce median hospital length of stay (mean difference, −5 days [CI, −7.7 to −2.3 days] and 0 days [CI, −4.0 to 4.0 days]; 2 RCTs) (low COE). However, remdesivir probably does not decrease the percentage of patients hospitalized between days 7 and 14 compared with standard care (4, 12).

**Time to Recovery or Clinical Improvement**

New analyses show that compared with control, remdesivir may result in a large reduction in time to recovery for patients with severe disease (5) and an uncertain reduction for patients with moderate disease (12). Remdesivir may result in a moderate reduction in median time to clinical improvement versus control (low COE) (13). The effect of remdesivir on time to recovery may not vary by age category, sex, symptom duration (≤10 days vs. >10 days or median duration ≤9 days vs. >9 days) (5, 13), disease severity (mild or moderate vs. severe [including critical]), or concomitant corticosteroid use (5). However, in patients with severe disease who are receiving invasive mechanical ventilation or ECMO at baseline (that is, those with critical COVID-19), remdesivir may not reduce time to recovery (5).

**Proportion Receiving Invasive Ventilation or ECMO at Follow-up or With Subsequent New Need for Ventilation**

New analyses show that remdesivir may result in a small reduction in the percentage of patients receiving invasive mechanical ventilation or ECMO (new need or continued use from baseline) at specific follow-up time points between days 11 and 15 (11.3% [100 of 887] vs. 16.5% [132 of 799]; ARD, −4.8% [CI, −8.0% to −1.5%]; 3 RCTs). However, on the basis of Solidarity data, remdesivir probably results in little to no difference in subsequent new need for ventilation (invasive or noninvasive mechanical ventilation or ECMO) (11.9% [295 of 2489] vs. 11.5% [284 of 2475]; ARD, 0.4% [CI, −1.4% to 2.2%]; 1 RCT) (low COE) (Figure 2, middle).

**Adverse Events**

New analyses show that remdesivir probably reduces serious adverse events by a moderate amount (ARD, −6.3% [CI, −10.2% to −2.4%]; 3 RCTs) (moderate COE) (Figure 2, bottom) and may result in little to no difference in any adverse event (ARD, −0.3% [CI, −5.0% to 4.4%]; 3 RCTs) (low COE). Of note, serious adverse events reported in trials included a combination of clinical findings resulting from COVID-19 progression (such as
respiratory failure and need for endotracheal intubation) and direct remdesivir toxicity.

**Remdesivir 10-Day Course Compared With Placebo**

The inclusion of final results from ACTT-1 led to updated conclusions that a 10-day course of remdesivir compared with placebo may result in a moderate reduction in hospital length of stay, a large reduction in time to recovery, and a moderate reduction in the proportion of patients receiving invasive mechanical ventilation or ECMO at follow-up (5). Our other conclusions remain unchanged (Table and Appendix Table).

**Remdesivir 10-Day Course Compared With Standard Care**

The inclusion of Solidarity results led to updated conclusions that compared with standard care, remdesivir probably results in little to no difference in mortality (4, 12). Remdesivir probably does not decrease the subsequent need for ventilation in patients not receiving it at baseline (4) or the percentage of persons hospitalized between days 7 and 14 (4, 12). Using 28-day data from SIMPLE-2 (12), we now conclude that remdesivir may result in a moderate increase in the proportions recovered and clinically improved. Our other conclusions remain unchanged (Table and Appendix Table).

**Duration of Remdesivir Therapy: 5 Versus 10 Days (2 Trials)**

For the 2 previously published RCTs comparing 5 versus 10 days of remdesivir therapy in patients with moderate and severe COVID-19 (11, 12), we determined aggregate COEs.

Our reanalysis of previous publications shows that for hospitalized patients not requiring invasive mechanical ventilation or ECMO, a 5-day course of remdesivir, compared with a 10-day course, may result in a moderate increase in the proportion clinically improved, a small reduction in time to recovery, a small reduction in the percentage of patients receiving mechanical ventilation or ECMO, and a moderate reduction in serious adverse events, but may not decrease the percentage of persons hospitalized between days 11 and 14 (Table).

Results from a previously reported post hoc analysis found that among patients whose condition worsened clinically so that they needed invasive mechanical ventilation or ECMO despite a 5-day course of remdesivir, continuing remdesivir through 10 days resulted in a lower mortality rate (ARD, 23.0% [CI, 1.0% to 45.0%]) (3, 11). However, we downgraded the COE from our previous assessment of low certainty to insufficient because of the post hoc nature of analysis, a small sample size (n = 66), and relatively few events.

**DISCUSSION**

Our updated living review and meta-analyses are derived from 5 RCTs of remdesivir enrolling 7767 patients worldwide. Information from Solidarity, the largest RCT, contributes 78% of all deaths to our mortality analyses. The substantive new evidence changes the nature and strength of our earlier conclusions.

For our main analysis, we selected the effect of a 10-day course of remdesivir (intervention) on mortality compared with a placebo or standard care control (comparator). All-cause mortality is an important unbiased measure of treatment effectiveness and allowed us to pool findings from both the placebo and standard-of-care studies. A 10-day course of remdesivir was chosen as the primary intervention because it was used in 4 of the 5 RCTs (4, 5, 12, 13).

The results of the 2 largest trials (ACTT-1 and Solidarity), both of which enrolled patients with all severities of COVID-19 (including severe and critical), vary slightly in their point estimate on the effect of remdesivir on mortality. However, neither trial showed a statistically significant lower mortality rate with remdesivir, and the numerically lower mortality rate seen with remdesivir in ACTT-1 is fairly consistent with results from the larger Solidarity trial (which was powered for mortality). Furthermore, differences in geographic location, prevalence of concomitant steroid use, or control (placebo vs. standard care) seem unlikely to account for the slightly varied results. Therefore, for adults hospitalized with COVID-19, a 10-day course of remdesivir compared with placebo or standard care probably results in little to no mortality difference.

New information allowed us to assess the effect of remdesivir on mortality in clinically meaningful subgroups. A 10-day course of remdesivir versus control may result in little to no mortality reduction in patients not receiving supplemental oxygen, a small mortality reduction in those receiving supplemental oxygen and not needing ventilation, and a moderate increase in mortality in patients receiving ventilation. However, effects of remdesivir on mortality may not vary by other patient or disease characteristics, including symptom duration (≤10 vs. >10 days). Furthermore, the effect of remdesivir on mortality and time to recovery did not vary by concomitant corticosteroid use in sensitivity analyses, an important finding given that treatment with dexamethasone reduces mortality in patients with severe or critical COVID-19 (14). Our subgroup results are based on post hoc analyses, which limits the credibility of their findings. However, the results are consistent across studies and are useful for clinical decision making. Furthermore, because the U.S. Food and Drug Administration has approved remdesivir (15), it is unlikely that substantial new information comparing remdesivir with control will be published (16-18).

The effects of remdesivir on nonfatal outcomes generally showed a benefit. Compared with control, remdesivir may result in a small reduction in the percentage of patients receiving invasive mechanical ventilation or ECMO at specific follow-up time points (11 to 15 days). However, Solidarity results suggest that it probably results in little to no difference in new need for ventilation. These varied results across trials are probably the result of differences in study population and outcome ascertainment. Although 3 RCTs followed all participants, including those receiving mechanical ventilation at baseline, to determine the proportion receiving mechanical ventilation at specific time points, Solidarity reported only new need for ventilation in patients not receiving...
ventilation at baseline. Remdesivir compared with control probably results in moderate to large reductions in median time to clinical improvement or recovery and a moderate increase in percentage recovered or clinically improved. The effect of remdesivir on hospitalization status (length of stay or percentage hospitalized between days 7 and 14) is mixed, perhaps in part because of continued hospitalization while remdesivir is being administered. Remdesivir probably reduces serious adverse events, some of which include measures of COVID-19 progression, by a moderate amount.

Updated results strengthen our previous findings that among patients not requiring mechanical ventilation or ECMO, a 5-day course of remdesivir versus a 10-day course may have net benefit. Furthermore, a 5-day course would lower drug and resource costs associated with remdesivir infusion.

The U.S. Food and Drug Administration recently approved remdesivir for patients with COVID-19 who are older than 12 years, weigh more than 40 kg, and are hospitalized or in a facility that can provide care similar to that of an acute care hospital (15). Recommendations on the use of remdesivir for COVID-19 vary. Whereas the WHO conditionally recommends against the use of remdesivir (19), the National Institutes of Health and the Infectious Diseases Society of America continue to recommend remdesivir for selected patients on the basis of disease severity (20, 21). The Scientific Medical Policy Committee used our updated systematic review to develop a new Practice Points document to guide clinicians on remdesivir use (22).

The Institute for Clinical and Economic Review recently updated its assessment on pricing models for remdesivir to include findings from Solidarity (23). It concluded that remdesivir does not meet a key cost-effectiveness threshold of $50,000 per quality-adjusted life-year for any severity of COVID-19 as currently priced ($3120 for a 5-day [6-vial] course). If remdesivir were priced at $2470 for the 9-vial patient treatment course similar to the average course in ACTTT-1, it would meet the cost-effectiveness benchmark for treating patients similar to those enrolled in ACTTT-1 (5) (that is, patients receiving nasal oxygen, mechanical ventilation, or ECMO [severe or critical COVID-19]). However, remdesivir is unlikely to be priced at $70 per 5-day treatment course, the price needed to meet cost-effectiveness for patients similar to those enrolled in SIMPLE-2 (12) (that is, patients not needing respiratory support [mild or moderate COVID-19]). Gilead has an ongoing placebo-controlled RCT evaluating the efficacy and safety of intravenous remdesivir (3-day course) for outpatients with mild or moderate, early-stage COVID-19 (≤7 days of symptoms) who are at risk for progression to severe disease (24). Given the logistic challenges of administering intravenous therapies to outpatients with COVID-19, Gilead is also investigating an inhaled solution of remdesivir for such patients (25, 26).

The evidence base for effectiveness is derived from 5 RCTs, including various countries of enrollment; differences in control (placebo vs. standard care); heterogeneity in definitions of COVID-19 severity at baseline that did not fully align with those from the National Institutes of Health, WHO, or the U.S. Food and Drug Administration; and diverse outcomes. Given these differences, decisions on pooling results across trials, including for subgroups, were made after discussions between review authors and the Scientific Medical Policy Committee. Studies were pooled when they were deemed to be clinically similar, with the goal of providing useful analyses. We also provide information separately for individual trials, placebo and standard care control groups, and 5- and 10-day treatment durations.

The evidence base for remdesivir harms is derived from 3 RCTs. Because adverse events reported in RCTs included both adverse effects of remdesivir and indicators of COVID-19 disease progression, our conclusion that remdesivir probably reduces serious adverse events may not accurately differentiate the effect of remdesivir on these physiologically disparate events. Furthermore, the largest study, Solidarity, has recorded serious adverse reactions (limited to suspected drug-related events considered rare, life-threatening, and unexpected), but the published interim results do not report these results. Future availability of this information may affect our conclusions. Of note, pregnant women, children younger than 12 years, and persons with severe kidney or liver dysfunction were excluded from studies, and these results cannot be extrapolated to those populations.

In conclusion, in hospitalized adults with COVID-19, remdesivir probably results in little to no difference in mortality and no more than a small reduction in the need for ventilation, but it probably improves the percentage recovered and reduces serious adverse events. For patients not receiving ventilation, a 5-day course may provide greater benefits and fewer harms, with lower drug costs, than a 10-day course.

From Minneapolis VA Health Care System and University of Minnesota School of Medicine, Minneapolis, Minnesota (A.S.K., W.D., T.J.W.); Minneapolis VA Health Care System, Minneapolis, Minnesota (R.M., N.G.); and VA Portland Health Care System, Portland, Oregon (K.V., A.O.).

Acknowledgment: The authors thank Eric Linskens for his assistance with the creation of the plots using R.

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-8148.

Reproducible Research Statement: Study protocol: Not available. Statistical code: Available from Mr. MacDonald (e-mail, Roderick.macdonald@va.gov). Data set: See the Supplement (available at Annals.org).

Corresponding Author: Timothy J. Wilt, MD, MPH, Minneapolis VA Health Care System, One Veterans Drive (111-0), Minneapolis, MN 55417; e-mail, Tim.Wilt@va.gov.
Correction: This article was corrected on 24 February 2021 to correct the description of the magnitude of the mortality reduction with remdesivir for patients receiving supplemental oxygen but not needing ventilation.

Current author addresses and author contributions are available at Annals.org.

References
1. Mulangu S, Dodd LE, Davey RT Jr, et al; PALM Writing Group. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019;381:2293-303. [PMID: 31774950] doi:10.1056/NEJMoa1910993
2. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. [PMID: 32264556] doi:10.1038/s41467-019-13940-6
3. Wilt TJ, Kaka AS, MacDonald R, et al. Remdesivir for adults with COVID-19: a living systematic review for an American College of Physicians Practice Points. Ann Intern Med. 2020. doi:10.7326/M20-5752
4. Pan H, Peto R, Henao-Restrepo AM, et al; WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19—interim WHO Solidarity trial results. N Engl J Med. 2020. [PMID: 33264556] doi:10.1056/NEJMoa2023184
5. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19—final report. N Engl J Med. 2020;383:1813-1826. [PMID: 32445440] doi:10.1056/NEJMoa2007764
6. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011. Accessed at http://handbook.cochrane.org on 24 July 2020.
7. Schünemann H, Brozek J, Guyatt G, et al, eds. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Accessed at https://gdt.gradepro.org/app/handbook/handbook.html on 2 June 2020.
8. Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1-48.
9. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
10. Wilt TJ, Kaka AS, MacDonald R, et al. Rapid Response: COVID-19: Remdesivir for Hospitalized Adults. Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs; 2020. VA ESP Project 09-09.
11. Goldman JD, Lye DCB, Hui DS, et al; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020;383:1827-37. [PMID: 32459919] doi:10.1056/NEJMoa2015301
12. Spinner CD, Gottlieb RL, Criner GJ, et al; GS-US-540-5774 Investigators. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-57. [PMID: 32821939] doi:10.1001/jama.2020.16349
13. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multi-centre trial. Lancet. 2020;395:1569-78. [PMID: 32423584] doi:10.1016/S0140-6736(20)31022-9
14. Horby P, Lim WS, Emberson JR, et al; RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020. [PMID: 32678530] doi:10.1056/NEJMoa2021436
15. U.S. Food and Drug Administration. FDA approves first treatment for COVID-19. Accessed at www.fda.gov/news-events /press-announcements/fda-approves-first-treatment-covid-19 on 3 November 2020.
16. Harrington DP, Baden LR, Hogan JW. A large, simple trial leading to complex questions [Editorial]. N Engl J Med. 2020. [PMID: 33264557] doi:10.1056/NEJMe2034294
17. Hsu J. Covid-19: what now for remdesivir. BMJ. 2020;371: m4457. [PMID: 33214186] doi:10.1136/bmj.m4457
18. McCready EK, Angus DC. Efficacy of remdesivir in COVID-19 [Editorial]. JAMA. 2020;324:1041-2. [PMID: 32821934] doi:10.1001/jama.2020.16337
19. Siemieniuk R, Rochweg B, Afrominas T, et al. A living WHO guideline on drugs for Covid-19. BMJ. 2020;370:m3379. [PMID: 32887691] doi:10.1136/bmj.m3379
20. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Accessed at www.idsociety.org /practice-guideline/covid-19-guideline-treatment-and-management /#toc-8 on 21 December 2020.
21. National Institutes of Health. Therapeutic management of patients with COVID-19. Accessed at www.covid19treatmentguidelines.nih.gov/therapeutic-management on 21 December 2020.
22. Qaseem A, Yost J, Etzeindia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (version 2). Ann Intern Med. 9 February 2020. [Epub ahead of print]; doi:10.7326/M20-8101
23. Institute for Clinical and Economic Review. ICER provides second update to pricing models for remdesivir as a treatment for COVID-19. Accessed at https://icer.org/pressreleases/icer-provides-second-update-to-pricing-models-for-remdesivir-as-a-treatment-for-covid-19 on 8 December 2020.
24. Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting [clinical trial]. Accessed at https://clinicaltrials.gov/ct2/show/NCT04539262 on 21 December 2020.
25. Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation [clinical trial]. Accessed at https://clinicaltrials.gov/ct2/show/NCT04539262 on 21 December 2020.
26. Gilead Sciences. Gilead’s response to COVID-19. Accessed at www.gilead.com/purpose/advancing-global-health/covid-19 on 21 December 2020.
Current Author Addresses: Dr. Kaka: Minneapolis VA Health Care System, One Veterans Drive (111-F), Minneapolis, MN 55417.
Mr. MacDonald and Drs. Greer, Duan-Porter, and Wilt: Minneapolis VA Health Care System, One Veterans Drive (111-0), Minneapolis, MN 55417.
Ms. Vela: 5696 South Apsley Way, Boise, ID 83709.
Dr. Obley: Portland VA Health Care System, 3710 Southwest U.S. Veterans Hospital Road, Portland, OR 97239.

Author Contributions: Conception and design: A.S. Kaka, T.J. Wilt.
Analysis and interpretation of the data: A.S. Kaka, R. MacDonald, N. Greer, W. Duan-Porter, A. Obley, T.J. Wilt.
Drafting of the article: A.S. Kaka, R. MacDonald.
Critical revision for important intellectual content: R. MacDonald, N. Greer, W. Duan-Porter, A. Obley, T.J. Wilt.
Final approval of the article: A.S. Kaka, R. MacDonald.
Provision of study materials or patients: N. Greer.
Statistical expertise: R. MacDonald, T.J. Wilt.
Obtaining of funding: T.J. Wilt.
Administrative, technical, or logistic support: R. MacDonald, N. Greer, T.J. Wilt.
Collection and assembly of data: N. Greer, R. MacDonald, K. Vela, T.J. Wilt.

Appendix Figure. Evidence search and selection.

Abstracts reviewed  
(n = 1317)

Abstracts excluded  
(n = 1124)

Full-text articles 
reviewed (n = 193)

Excluded (n = 188)  
Not randomized controlled trial: 35  
Systematic review or meta-analysis: 46  
Letter, commentary, narrative review, or protocol: 106  
Study population not adults: 0  
Not published in English: 1

Included (n = 5 trials)
### Appendix Table. Effect of Remdesivir in Randomized Controlled Studies

| Comparison | Study, Year (Reference); Assessment | Absolute Effect of Remdesivir vs. Control | Certainty of Evidence* | Summary† |
|------------|-------------------------------------|------------------------------------------|------------------------|----------|
| **All-cause mortality** | | | | |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1682) | Solidarity, 2020 (11); 11 d; Wang et al, 2020 (13); 28-29 d | 77.3% (683/884) vs. 71.6% (571/798) | Pooled ARD, 6.5% (CI, 2.4% to 10.7%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 10-d course vs. placebo, 2 trials (n = 1289) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 73.8% (399/541) vs. 67.6% (352/521) | Pooled ARD, 6.2% (CI, 0.7% to 11.7%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 10-d course vs. SC, 1 trial (n = 391) |Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 92.2% (178/193) vs. 85% (170/200) | Pooled ARD, 7.2% (CI, 1.0% to 13.5%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 781) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 91.6% (175/191) vs. 85% (170/200) | Pooled ARD, 6.6% (CI, 0.3% to 12.9%) | Moderate | Remdesivir 5-d course may result in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1682) | Solidarity, 2020 (11); 11 d; Wang et al, 2020 (13); 28-29 d | 73.8% (399/541) vs. 67.6% (352/521) | Pooled ARD, 6.2% (CI, 0.7% to 11.7%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 1289) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 92.2% (178/193) vs. 85% (170/200) | Pooled ARD, 7.2% (CI, 1.0% to 13.5%) | Moderate | Remdesivir 5-d course may result in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 5-d course vs. SC, 1 trial (n = 391) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 91.6% (175/191) vs. 85% (170/200) | Pooled ARD, 6.6% (CI, 0.3% to 12.9%) | Moderate | Remdesivir 5-d course may result in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 781) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 91.6% (175/191) vs. 85% (170/200) | Pooled ARD, 6.6% (CI, 0.3% to 12.9%) | Moderate | Remdesivir 5-d course may result in a moderate increase in percentage recovered vs. placebo or SC |
| **Proportion of patients recovered†‡** | | | | |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1682) | Solidarity, 2020 (11); 11 d; Wang et al, 2020 (13); 28-29 d | 77.3% (683/884) vs. 71.6% (571/798) | Pooled ARD, 6.5% (CI, 2.4% to 10.7%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 10-d course vs. placebo, 2 trials (n = 1289) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 73.8% (399/541) vs. 67.6% (352/521) | Pooled ARD, 6.2% (CI, 0.7% to 11.7%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 10-d course vs. SC, 1 trial (n = 391) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 92.2% (178/193) vs. 85% (170/200) | Pooled ARD, 7.2% (CI, 1.0% to 13.5%) | Moderate | Remdesivir 10-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 781) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 73.8% (141/191) vs. 68.4% (112/193) | Pooled ARD, 5.4% (CI, −3.6% to 14.5%) | Moderate | Remdesivir 5-d course probably results in a moderate increase in percentage recovered vs. placebo or SC |
| **Clinical improvement** | | | | |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1682) | Solidarity, 2020 (11); 11 d; Wang et al, 2020 (13); 28-29 d | 65.2% (103/158) vs. 57.7% (45/78) | Pooled ARD, 7.5% (CI, −5.7% to 20.7%) | Moderate | Remdesivir 10-d course may result in a moderate increase in clinical improvement vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 1289) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 28 d | 89.5% (171/191) vs. 83% (164/200) | Pooled ARD, 6.5% (CI, −0.3% to 13.3%) | Moderate | Remdesivir 5-d course may result in a moderate increase in clinical improvement vs. placebo or SC |
| Remdesivir 5-d course vs. placebo, 2 trials (n = 781) | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 70.2% (134/191) vs. 65.3% (126/193) | Pooled ARD, 4.9% (CI, −4.5% to 14.2%) | Moderate | Remdesivir 5-d course may result in a moderate increase in clinical improvement vs. placebo or SC |
| **Hospital LOS** | | | | |
| Remdesivir 10-d course vs. placebo, 2 trials (n = 1299) | Beigel et al (ACTT-1), 2020 (5); 29 d | Initial hospitalization | Median, 12 (IQR, 6 to 28 d) vs. 17 d (IQR, 8 to 28 d) | Low†† | Remdesivir 10-d course may result in a moderate reduction in median hospital LOS vs. placebo |

Continued on following page
### Appendix Table—Continued

| Comparison                                                                 | Study, Year (Reference); Assessment Time Point | Absolute Effect of Remdesivir vs. Control | Certainty of Evidence | Summary† |
|---------------------------------------------------------------------------|-----------------------------------------------|------------------------------------------|-----------------------|----------|
| **Time to recovery or clinical improvement**                              |                                               |                                          |                       |          |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1674)             | Beigel et al, 2020 (5); Spinner et al, 2020 (12); Wang et al, 2020 (13); 11–29 d | Difference in medians ranged from −1 to 5 | Low§                  | Remdesivir 10-d course may result in an uncertain reduction in time to recovery in patients with moderate severity at day 11 and up to a large reduction in patients with severe disease at day 29 and a moderate reduction in median time to clinical improvement in patients with severe disease vs. control |
| Remdesivir 10-d course vs. placebo; 2 trials (n = 1299)                   | Beigel et al (ACTT-1), 2020 (5); 29 d         | Median, 10 (CI, 9 to 11 d) vs. 15 d (CI, 13 to 18 d) P < 0.001 Rate ratio, 1.29 (CI, 1.12 to 1.49) Median, 21 (IQR, 13 to 28 d) vs. 23 d (IQR, 18 to 36 d); HR, 1.23 (CI, 0.87 to 1.75) | Low‡‡                  | Remdesivir 10-d course may result in a large reduction in median time to recovery and a moderate reduction in median time to clinical improvement vs. placebo (Time to recovery did not vary by age, sex, symptom duration (≤10 vs >10 d), or disease severity (5)) |
| Remdesivir 10-d course vs. placebo, SC; 1 trial (n = 393)                | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | Median, 8 (IQR, 4 to 13 d) vs. 7 d (IQR, 4 to 15 d); HR, 1.11 (CI, 0.90 to 1.36) | Insufficient§§        | -        |
| Remdesivir 5-d course vs. placebo, SC; 1 trial (n = 391)                 | Recovery                                        | Median, 4 (IQR, 5 to 10 d) vs. 7 d (IQR, 4 to 15 d); HR, 1.18 (CI, 0.96 to 1.45) | Low††                  | Remdesivir 5-d course may result in a small reduction in median time to recovery vs. placebo |
| Remdesivir 10-d course vs. remdesivir 10-d course, 2 trials (n = 781)     | Recovery                                        | Median, 10 (IQR, 6 to 18 d) vs. 11 d (IQR, 7 to not able to estimate); P = NS, HR, 0.81 (CI, 0.64 to 1.04) | Low§                  | Remdesivir 10-d course may result in a small reduction in median time to recovery vs. 10-d course |

| Proportion receiving invasive ventilation/ECMO at follow-up][[1]]          |                                               |                                          |                       |          |
| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1688)             | Beigel et al, 2020 (5); Spinner et al, 2020 (12); Wang et al, 2020 (13); 11–15 d | 11.3% (100/887) vs. 16.5% (132/799); POOLED ARD, −4.8% (CI, −8.0% to −1.5%) | Low§                  | Remdesivir 10-d course may result in a small reduction in proportion receiving mechanical ventilation or ECMO at follow-up vs. placebo or SC |
| Remdesivir 10-d course vs. placebo, 2 trials (n = 1299)                   | Beigel et al (ACTT-1), 2020 (5); Wang et al, 2020 (13) | 17.6% (95/541) vs. 23.2% (121/521); ARD, −5.7% (CI, −10.5% to 0.8%) 2.6% (4/153) vs. 9.0% (7/78); ARD, −6.4% (CI, −13.2% to 0.5%) | Low§                  | Remdesivir 10-d course may result in a moderate reduction in proportion receiving mechanical ventilation or ECMO at follow-up vs. placebo or SC |
| Remdesivir 10-d course vs. SC, 1 trial (n = 393)                         | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12) | 0.5% (1/193) vs. 2.0% (4/200); ARD, −1.5% (CI, −3.7% to 0.7%) | Low§                  | Remdesivir 10-d course may result in a small reduction in proportion receiving mechanical ventilation or ECMO at follow-up vs. SC |
| Remdesivir 5-d course vs. SC, 1 trial (n = 391)                          | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12) | 0% (0/191) vs. 2.0% (4/200); ARD, −2.0% (CI, −4.2% to 0.2%) | Low§                  | Remdesivir 5-d course may result in a small reduction in proportion receiving mechanical ventilation or ECMO at follow-up vs. SC |
| Remdesivir 5-d course vs. remdesivir 10-d course, 2 trials (n = 781)     | Goldman et al (GS-US-540-5773: SIMPLE-1), 2020 (11); Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12) | 8.0% (16/200) vs. 16.8% (33/197); ARD, −8.8% (CI, −15.2% to −2.3%); 0% (0/191) vs. 0.5% (1/193); ARD, −0.5% (CI, −1.9% to 0.9%) | Low¶¶                  | Remdesivir 5-d course may result in a small reduction in proportion receiving mechanical ventilation or ECMO or vs. 10-d course at follow-up Range of ARDs, −8.8% to −0.5% (Observed effects may vary on the basis of the baseline disease severity of the enrolled patients in each trial, i.e., severe disease in SIMPLE-1 and moderate disease in SIMPLE-2) |

Subsequent need for ventilation (invasive or noninvasive mechanical ventilation, or ECMO) in those not receiving ventilation at baseline

| Remdesivir 10-d course vs. SC, 1 trial (n = 4964) (4)                   | Follow-up through day 28                      | 11.9% (295/2489) vs. 11.5% (284/2475); ARD, 0.4% (CI, −1.4% to 2.2%) | Moderate†               | Remdesivir 10-d course probably results in little to no difference in new need for ventilation vs. SC |

Any adverse event (includes markers of COVID-19 progression and remdesivir toxicity)

| Remdesivir 10-d course vs. placebo or SC, 3 trials (n = 1674)           | Beigel et al, 2020 (5); Spinner et al, 2020 (12); Wang et al, 2020 (13); 11–29 d | 59.1% (520/880) vs. 58.7% (466/794); POOLED ARD, −0.3% (CI, −5.0% to 4.4%) | Low¶¶                  | Remdesivir 10-d course may result in little to no difference in any adverse events vs. control |
| Remdesivir 10-d course vs. placebo, 2 trials (n = 1281)                 | Beigel et al (ACTT-1), 2020 (5); Wang et al, 2020 (13); 28 d | 57.3% (305/532) vs. 62.6% (323/516); ARD, −5.3% (CI, −11.2% to 0.7%) 6.5% (102/155) vs. 44.1% (50/78); ARD, 1.7% (CI, −11.3% to 14.7%) | Low¶¶                  | Remdesivir 10-d course may result in a small reduction in any adverse events vs. placebo Range of ARDs, −5.3% to 1.7% |
| Remdesivir 10-d course vs. SC, 1 trial (n = 393)                       | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 58.5% (113/193) vs. 47.9% (93/200); ARD, 12.6% (CI, 2.2% to 21.9%) | Low¶                   | Remdesivir 10-d course may result in a moderate increase in any adverse events vs. SC |
| Remdesivir 5-d course vs. SC, 1 trial (n = 391)                        | Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 51.3% (98/191) vs. 47.5% (93/200); ARD, 4.8% (CI, −5.1% to 14.7%) | Low¶                   | Remdesivir 5-d course may result in a small increase in any adverse events vs. SC |
| Remdesivir 5-d course vs. remdesivir 10-d course, 2 trials (n = 781)   | Goldman et al (GS-US-540-5773: SIMPLE-1), 2020 (11); Spinner et al (GS-US-540-5774: SIMPLE-2), 2020 (12); 11 d | 70.5% (141/200) vs. 73.6% (145/197); ARD, −3.1% (CI, −11.9% to 5.7%) 51.3% (98/191) vs. 58.5% (113/193); ARD, −7.2% (CI, −17.2% to 2.7%) | Low¶†                  | Remdesivir 5-d course may result in a moderate reduction in any adverse events vs. 10-d course Range of ARDs, −7.2% to −3.1% |

Continued on following page
### Appendix Table—Continued

| Comparison | Study, Year (Reference); Assessment Time Point | Absolute Effect of Remdesivir vs. Control | Certainty of Evidence* | Summary† |
|------------|---------------------------------------------|------------------------------------------|------------------------|----------|
| Remdesivir 10-d course vs. placebo or SC; 3 trials (n = 1674) | Beigel et al, 2020 (5); Spinner et al, 2020 (12); Wang et al, 2020 (13); 11-29 d | 19.2% (169/880) vs. 25.3% (201/794) Pooled ARD, −6.3% (CI, −10.2% to −2.4%) | Moderate†† | Remdesivir 10-d course probably results in a moderate reduction in serious adverse events vs. control |
| Remdesivir 10-d course vs. placebo; 2 trials (n = 1299) | Beigel et al (ACTT-1); 2020 (5), 29 d | 24.6% (131/532) vs. 31.6% (163/514) ARD, −7.0% (CI, −12.4% to −1.5%) | Moderate†† | Remdesivir 10-d course probably results in a moderate reduction in serious adverse events vs. placebo |
| Remdesivir 10-d course vs. SC; 1 trial (n = 393) | Spinner et al (GS-US-540-5774: SIMPLE-2); 2020 (12); 11 d | 5.2% (10/193) vs. 9.0% (18/200) ARD, −3.8% (CI, −8.9% to 1.2%) | Low§§ | Remdesivir 10-d course may result in a small reduction in serious adverse events vs. SC |
| Remdesivir 5-d course vs. SC; 1 trial (n = 391) | Spinner et al (GS-US-540-5774: SIMPLE-2); 2020 (12); 11 d | 4.7% (9/191) vs. 9.0% (18/200) ARD, −4.3% (CI, −9.3% to 0.7%) | Low§§ | Remdesivir 5-d course may result in a small reduction in serious adverse events vs. SC |
| Remdesivir 5-d course vs. remdesivir 10-d course; 2 trials (n = 781) | Goldman et al (GS-US-540-5773: SIMPLE-1); 2020 (11); 14 d | 21.0% (42/200) vs. 34.5% (68/197) ARD, −13.5% (CI, −22.2% to −4.8%) | Low¶¶ | Remdesivir 5-d course may result in a moderate reduction in serious adverse events vs. 10-d course |
| | Spinner et al (GS-US-540-5774: SIMPLE-2); 2020 (12); 11 d | 4.7% (9/191) vs. 5.2% (10/193) ARD, −0.5% (CI, −4.8% to 3.9%) | Low¶¶ | Range of ARDs, −7.6% to −7.0% |

ACTT-1 = Adaptive COVID-19 Treatment Trial; ARD = absolute risk difference; COVID-19 = coronavirus disease 2019; ECMO = extracorporeal membrane oxygenation; HR = hazard ratio; IQR = interquartile range; LOS = length of stay; MD = mean difference; NR = not reported; NS = not statistically significant; SC = standard care; SIMPLE-2 = Study to Evaluate the Safety and Antiviral Activity of Remdesivir [GS-5734] in Participants With Moderate Coronavirus Disease [COVID-19] Compared to Standard of Care Treatment.

* GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group grades of evidence are as follows: High certainty: We are very confident that the true effect lies close to the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate. The true effect is probably close to the estimate of the effect, but a possibility exists that it is substantially different. Low certainty: Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate. The true effect is probably substantially different from the estimate of the effect.

† Thresholds for determining magnitude by outcome are as follows: All-cause mortality: little or no effect, <1%; small effect, 1%-2.9%; moderate effect, 3%-4.9%; large effect, ≥5%. Recovery: little or no effect, <2%; small effect, 2%-4.9%; moderate effect, 5%-9.9%; large effect, ≥10%. Clinical improvement: little or no effect, <2%; small effect, 2%-4.9%; moderate effect, 5%-9.9%; large effect, ≥10%. LOS: little or no effect, <1 d; small effect, ≥1-2 d; moderate effect, >2 to <3 d; large effect, ≥3 d. Time to recovery or clinical improvement: little or no effect, <1 d; small effect, ≥1-2 d; moderate effect, >2 to <3 d; large effect, ≥3 d. Mechanical ventilation or ECMO: little or no effect, <1%; small effect, 1%-4.9%; moderate effect, 5%-9.9%; large effect, ≥10%. Any adverse event: little or no effect, <2%; small effect, 2%-4.9%; moderate effect, 5%-19.9%; large effect, ≥20%. Severe adverse event: little or no effect, <1%; small effect, 1%-4.9%; moderate effect, 5%-9.9%; large effect, ≥10%.

‡ Downgraded for imprecision.
§ Downgraded 2 levels for imprecision (very wide CIs) or sparse data.
¶ Downgraded 2 levels for study limitations and imprecision (wide CIs).
‖ Defined as discharge from the hospital or hospitalization for infection control purposes only (5) or discharge from the hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care (11-13).
** Defined as a 2-point reduction in patient admission status on a 6-point ordinal scale (1 = live discharge to 6 = death) or live discharge from the hospital, whichever came first (13), or as an improvement of at least 2 points from baseline on a 7-point ordinal scale (1 = death to 7 = discharged from hospital) (11, 12).
†† Downgraded 2 levels for imprecision and inconsistency.
‡‡ Downgraded 2 levels for difficulty in interpreting precision and inconsistency.
§§ Downgraded to insufficient for difficulty in interpreting results (HR not reported for 5-d vs. 10-d course) and higher median with 10-d course vs. SC, but reduction in time to recovery favors 10-d course on the basis of HR.
¶¶ Day 11 in Spinner et al (12), day 14 in Wang et al (13), and day 15 in ACTT-1 (5).
¶¶¶ Downgraded 2 levels for imprecision and inconsistency.